Viewing Study NCT03317366

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:16 PM
Ignite Modification Date: 2026-06-14 @ 5:50 PM
Study NCT ID: NCT03317366
Status: NO_LONGER_AVAILABLE
Last Update Posted: 2021-08-06
First Post: 2017-10-17
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Proteus Syndrome View
None PIK3CA-Related Overgrowth Spectrum (PROS) View
None Growth Disorders View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ARQ 092 View
None ArQule View
None AKT View
None PIK3CA View
None Overgrowth View
None Congenital malformations View